Amanote Research
Register
Sign In
Evolution of the Thienopyridine Class of Inhibitors of IkB Kinase-B: Part I: Hit-To-Lead Strategies
doi 10.1021/jm0510979.s001
Full Text
Open PDF
Abstract
Available in
full text
Date
Unknown
Authors
Unknown
Publisher
American Chemical Society (ACS)
Related search
Discovery of Wt RET and V804M RET Inhibitors: From Hit to Lead
ChemMedChem
Organic Chemistry
Molecular Medicine
Pharmacology
Biochemistry
Toxicology
Drug Discovery
Pharmaceutics
Structure Guided Development of Novel Thymidine Mimetics TargetingPseudomonas aeruginosaThymidylate Kinase: From Hit to Lead Generation
Journal of Medicinal Chemistry
Drug Discovery
Molecular Medicine
Kinase Inhibitors: A New Class of Antirheumatic Drugs
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Positive Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 4 (mGluR4). Part II: Challenges in Hit-To-Lead
Bioorganic and Medicinal Chemistry Letters
Organic Chemistry
Molecular Medicine
Molecular Biology
Biochemistry
Clinical Biochemistry
Pharmaceutical Science
Drug Discovery
Trends in Hit-To-Lead: An Update
Discovery, Synthesis, and in Vivo Activity of a New Class of Pyrazoloquinazolines as Selective Inhibitors of Aurora B Kinase
Hit Identification of CK2 Inhibitors by Virtual Screening
Biopolymers and Cell
Biochemistry
Genetics
Molecular Biology
I B Kinase: Beginning, Not the End
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Evolution of a New Class of VEGFR2 Inhibitors From Scaffold Morphing and Redesign
